Back

Hybrid coronary revascularization versus PCI for the treatment of high-risk patients with multivessel coronary artery disease: 2-year follow-up results from two institutions

31 August 2025 (13:15 - 14:00)
Organised by: Logo
Congress Presentation Part of: Revascularisation in coronary artery disease Revascularisation ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Professor Hua Yan

Wuhan Asia Heart Hospital, Wuhan (China)

7 More presentations in this session

Presentation thumbnail
Associations between dual trajectories of body mass index and waist-to-height ratio over a decade and incident coronary heart disease
Miss C. Huang (London, GB)
Abstract Slides Video
Presentation thumbnail
The EAPCI device success algorithm in the PIONEER IV trial: insights with angiography-derived FFR
Doctor A. Oshima (Galway, IE)
Abstract Slides Video
Presentation thumbnail
Invasive vs. conservative strategies in older patients with non-st-segment elevation myocardial infarction: an updated systematic review and meta-analysis
Doctor L. Lucena (Florianopolis, BR)
Abstract Slides Video
Presentation thumbnail
Impact of strut thickness on vessel responses after polymer-free biolimus A9-coated stents: both optical coherence tomographic and coronary angioscopic evaluations
Doctor M. Kusuda (Amagasaki, JP)
Abstract Slides Video
Presentation thumbnail
The association of aging and the efficacy of PCI in stable coronary artery disease. A secondary analysis of ORBITA-2.
Doctor F. Simader (London, GB)
Abstract Slides Video

Access the full session

Session thumbnail
Revascularisation in coronary artery disease

The Event

Event poster

ESC Congress 2025

31 August 2025 13:15 CET
You may be interested in
thumbnail
Congress Presentation
Hybrid coronary revascularization vs. coronary artery bypass grafting in multivessel coronary artery disease
thumbnail
Congress Session
Long-term outcomes and innovations in revascularisation strategies
thumbnail
Congress Session
Decision-making for revascularisation of multivessel disease

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources